NCT01457378

Brief Summary

The aim of this study performed in Irritable Bowel Syndrome (IBS) subjects and healthy patients is to demonstrate the ability of composite score of frequency of gastrointestinal symptoms to discriminate healthy subjects and IBS patients. The properties of this questionnaire of composite score of gastrointestinal symptoms frequency will be compared to other validated questionnaires (severity of IBS symptoms and HRQoL).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2011

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

October 19, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 24, 2011

Completed
8 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2011

Completed
Last Updated

September 20, 2016

Status Verified

September 1, 2016

Enrollment Period

1 month

First QC Date

October 19, 2011

Last Update Submit

September 19, 2016

Conditions

Keywords

Gastrointestinal symptomshealthy subjectsIBSHRQoLquestionnaires

Study Arms (2)

Healthy volunteers

100 healthy volunteers

IBS Subjects

100 IBS Subjects

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult healthy subjects and adult IBS patients (Rome III criteria, all subtype)

You may qualify if:

  • for Healthy subjects :
  • Healthy women and men free-living subject aged from 18 to 65 years.
  • Subject with a body mass index between 18 and 30, bounds included.
  • Subject having given written consent to take part in the study.
  • Chronic medical treatment-free excluding contraceptive and stable Hormonal Replacement Therapy
  • for IBS Patients :
  • IBS women and men free-living subject aged from 18 to 65 years
  • Subject with a diagnosis of IBS according to Rome III criteria: recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following: improvement with defecation; onset associated with a change in frequency of stool; onset associated with a change in form (appearance) of stool.
  • Subject with a diagnosis of IBS according to Rome III criteria with symptom onset at least 6 months prior to diagnosis.
  • Subject having an IBS-SSS score higher or equal to 75 corresponding to an active phase of IBS symptoms.
  • Subject having given written consent to take part in the study.

You may not qualify if:

  • for Healthy subjects :
  • Subject who, in the past, has consulted a general practitioner or a gastroenterologist for (IBS) or any other functional bowel disease including constipation and diarrhoea.
  • Subject with known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease
  • Subject treated with any chronic medical treatment that, in the investigator's opinion could interfere with the GI tract.
  • Subject who underwent general anaesthesia in the preceding 4 weeks.
  • Pregnant subject or breast-feeding subject at the time of the study.
  • Subject with known immunosuppression
  • Subject with any known food allergy
  • Subject in a situation, which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.
  • Subject not able to read, to understand and/or to answer to the questionnaires.
  • for IBS Patients :
  • If a subject fulfils with one of the following criteria, he/she must be excluded from the study:
  • Subject with a diagnosis of IBS with clinical signs of alarm (rectorragy, fever, associated inflammatory articular signs, recent weight loss).
  • Subject with known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease.
  • Subject who underwent general anaesthesia in the preceding 4 weeks.
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Eurofins Optimed

Gières, 38610, France

Location

Biofortis

Nantes, 44200, France

Location

Related Publications (1)

  • Azpiroz F, Guyonnet D, Donazzolo Y, Gendre D, Tanguy J, Guarner F. Digestive Symptoms in Healthy People and Subjects With Irritable Bowel Syndrome: Validation of Symptom Frequency Questionnaire. J Clin Gastroenterol. 2015 Aug;49(7):e64-70. doi: 10.1097/MCG.0000000000000178.

MeSH Terms

Conditions

Irritable Bowel Syndrome

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 19, 2011

First Posted

October 24, 2011

Study Start

September 1, 2011

Primary Completion

October 1, 2011

Study Completion

November 1, 2011

Last Updated

September 20, 2016

Record last verified: 2016-09

Locations